Agilon Health CEO resigns, suspends FY22 guidance.

• Pomerantz LLP investigates agilon health for securities fraud allegations • Investigation concerns whether agilon and its officers/directors engaged in unlawful practices • agilon's CEO and President, Steven Sell, resigned on August 4, 2025 • agilon suspended its full-year 2025 financial guidance due to market uncertainty • Investors advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 to join the class action.

New York, September 12, 2025 - Pomerantz LLP, a renowned law firm specializing in corporate, securities, and antitrust class litigation, has announced an investigation into allegations of securities fraud against Agilon Health, Inc. (NYSE: AGL). The investigation, led by Danielle Peyton, aims to determine whether Agilon and its officers or directors engaged in unlawful practices.

The investigation follows the resignation of Agilon's CEO and President, Steven Sell, on August 4, 2025. Sell's departure was accompanied by Agilon's decision to suspend its previously issued full-year 2025 financial guidance, citing market uncertainty and ongoing initiatives. The stock price of Agilon subsequently fell by $0.93 per share, or 51.51%, to close at $0.88 per share on August 5, 2025 Pomerantz Law Firm Investigates Claims On Behalf of Investors of agilon health, Inc. - AGL^[1].

Investors affected by these events are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to join a potential class action. Pomerantz LLP is known for its expertise in securities class actions and has a history of recovering multimillion-dollar damages on behalf of its clients Pomerantz Law Firm Investigates Claims On Behalf of Investors of agilon health, Inc. - AGL^[1].